Overview

Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects

Status:
NOT_YET_RECRUITING

Trial end date:
2028-10-01

Target enrollment:

Participant gender:

Summary

Evaluate the safety, tolerability, and objective response rate (ORR) of SHR2554 tablets in combination with other anti-tumor treatments in subjects with locally advanced or metastatic non-small cell lung cancer

Phase:

PHASE2

Details

Lead Sponsor:

Jiangsu HengRui Medicine Co., Ltd.

Treatments:

SHR-1701